kine thera bpc 157 BPC-157 — Provider-Supervised Peptide Therapy AOD-9604 Size:Hospira Pfizer® – Bacteriostatic Water | Case of 25 × 30 mL Vials 1000 mcg

kine thera bpc 157 BPC-157 — Provider-Supervised Peptide Therapy AOD-9604 Size:Hospira Pfizer® – Bacteriostatic Water | Case of 25 × 30 mL Vials 1000 mcg

AOD-9604

Subcutaneous planning from a 50 mg vial reconstituted with 3.0 mL BAC water (~16.7 mg/mL) Phase Days 1–2 (tolerance) Daily dose 2.5 mg once daily Units on U-100 syringe 15 units Volume 0.15 mL Phase Days 3+ (standard) Daily dose 5 mg once daily Units on U-100 syringe 30 units Volume 0.30 mL Phase Split option (BID) Daily dose 2.5 mg twice daily Units on U-100 syringe 15 units each Volume 0.15 mL each These subcutaneous examples come from informal research discussions

1000 mcg

Size:Hospira Pfizer® – Bacteriostatic Water | Case of 25 × 30 mL Vials

Each cell carries two grades: clinical evidence (human-RCT depth for this specific outcome) and community evidence (real-world adoption)